Clinical trials: Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder (HSDD)
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
- Trial name
- NCT03619005
- Testing
- Prasterone 6.5 mg (0.50%) Vaginal Insert
- Where
- 10 sites in United States
- Sponsor
- EndoCeutics Inc.
Hypoactive Sexual Desire Disorder
Lybrido for Female Sexual Dysfunction
The Lybrido study is a double-blind, randomized, placebo-controlled study with a 4-week baseline establishment period, 16 week treatment period and a follow up period for a total of 26 weeks on study.
- Trial name
- NCT01432665
- Testing
- Sildenafil, Testosterone
- Where
- 14 sites in United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Hypoactive Sexual Desire Disorder (HSDD)
Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
- Trial name
- NCT00349791
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 549 people
- Sponsor
- Warner Chilcott
Sexual Dysfunctions, Psychological
Flibanserin Versus Placebo in Premenopausal Women With HSDD
To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women.
- Trial name
- NCT00491829
- Testing
- 50 mg qhs, 100 mg
- Where
- 86 sites in Austria, Belgium and 11 more
- Volunteers
- 945 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunction, Psychological
Zestra in Women With Mixed Sexual Dysfunction
The objective of this study is to evaluate the clinical efficacy and safety of Zestra(TM) in women with acquired mixed desire/interest/arousal/orgasm disorders under conditions of home usage.
- Trial name
- NCT00118495
- Testing
- Non-prescription Zestra(TM): patented formulation
- Where
- 13 sites in United States
- Volunteers
- 200 people
- Sponsor
- QualiLife Pharmaceuticals
Sexual Dysfunctions, Psychological
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
- Trial name
- NCT00601367
- Testing
- flibanserin flexible dose
- Where
- 68 sites in Austria, Belgium and 10 more
- Volunteers
- 480 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction
BP101 for Adults With Female Sexual Dysfunction
This study is to confirm efficacy and safety of study drug BP101 in female patients with with decrease or loss of sexual desire, which is equal to acquired generalized hypoactive sexual desire disorder (HSDD).
- Conditions
- Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, Sexual Desire Disorder
- Trial name
- NCT03463707
- Testing
- BP101
- Where
- 20 sites in Russia
- Volunteers
- 205 people
- Sponsor
- Ivix LLX
Hypoactive Sexual Desire Disorder
Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder
A double-blind, randomized, placebo-controlled, dose-finding study to investigate the safety and efficacy of Lybridos in the domestic setting in healthy female subjects with hypoactive sexual desire disorder and maladaptive…
- Trial name
- NCT02101203
- Testing
- 0.5 mgTestosterone + 10 mg Buspirone
- Where
- 10 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.
- Trial name
- NCT00331123
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 562 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
This study is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of LibiGel® 300mcg in the treatment of HSDD in surgically menopausal women
- Trial name
- BLOOM (NCT00613002)
- Testing
- testosterone gel
- Where
- 63 sites in United States, Canada
- Volunteers
- 597 people
- Sponsor
- BioSante Pharmaceuticals
Hypoactive Sexual Desire Disorder (HSDD)
Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire
This is study of the efficacy, safety and pharmacokinetics of BP101 compared to placebo in patients with a decrease or loss of sexual desire.
- Trial name
- NCT03080298
- Testing
- BP101
- Where
- 12 sites in Russia
- Volunteers
- 119 people
- Sponsor
- Ivix LLX
Hypoactive Sexual Desire Disorder
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
- Trial name
- NCT03287232
- Testing
- Prasterone 6.5 mg (0.50%) Vaginal Insert
- Where
- 69 sites in United States, Canada
- Volunteers
- 653 people
- Sponsor
- EndoCeutics Inc.
Sexual Dysfunctions, Psychological
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
- Trial name
- NCT01188603
- Testing
- flibanserin 100 mg dose every evening
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder
To generate additional long-term safety and efficacy data on flibanserin in premenopausal women and establish long-term safety and tolerability of flibanserin in naturally postmenopausal women with Hypoactive Sexual Desire…
- Trial name
- NCT01103362
- Testing
- flibanserin
- Where
- 95 sites in United States, Canada
- Volunteers
- 596 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.
- Trial name
- NCT00331214
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 533 people
- Sponsor
- Warner Chilcott
Sexual Dysfunctions, Psychological
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
- Trial name
- NCT00996372
- Testing
- flibanserin
- Where
- 75 sites in United States
- Volunteers
- 949 people
- Sponsor
- Sprout Pharmaceuticals, Inc